INTRODUCTION: Older age has been associated to serious adverse events (AE) following yellow fever (YF) vaccination in passive surveillance studies, but few prospective studies involving seniors have been published. RESULTS: A total of 906 persons were evaluated; 78 were not vaccinated and 828 received the vaccine; 700 (84.7%) were interviewed after vaccination: 593 (84.7%) did not report any symptoms or signs following YF vaccine; 107 (15.3%) reported at least one AE temporally associated to YF vaccination: 97 (13.9%) had systemic AE and 17 (2.4%) reported AE at the injection site (7 had both systemic and local AE). Data regarding previous vaccination was available for 655 subjects. Statistically significant higher rates of systemic AE were observed among subjects who received the first YF vaccination (17.5%) in comparison to persons who had been previously vaccinated (9.5%). METHODS: This observational prospective study aimed to describe AE following YF vaccination in persons aged ≥ 60 y. From March 2009 to April 2010, seniors who sought YF vaccination at a reference Immunization Center in São Paulo city, Brazil, were included. Demographic and clinical data, previous YF vaccination, travel destination and the final decision regarding YF vaccination or not were collected from standardized medical records. Active AE assessment was done through telephone or electronic mail interview performed approximately 14 d after immunization. CONCLUSION: Most persons aged ≥ 60 y may be safely vaccinated against YF. Before vaccination, they must be carefully screened for conditions associated to altered immunocompetence and for risk of exposure to YF.
INTRODUCTION: Older age has been associated to serious adverse events (AE) following yellow fever (YF) vaccination in passive surveillance studies, but few prospective studies involving seniors have been published. RESULTS: A total of 906 persons were evaluated; 78 were not vaccinated and 828 received the vaccine; 700 (84.7%) were interviewed after vaccination: 593 (84.7%) did not report any symptoms or signs following YF vaccine; 107 (15.3%) reported at least one AE temporally associated to YF vaccination: 97 (13.9%) had systemic AE and 17 (2.4%) reported AE at the injection site (7 had both systemic and local AE). Data regarding previous vaccination was available for 655 subjects. Statistically significant higher rates of systemic AE were observed among subjects who received the first YF vaccination (17.5%) in comparison to persons who had been previously vaccinated (9.5%). METHODS: This observational prospective study aimed to describe AE following YF vaccination in persons aged ≥ 60 y. From March 2009 to April 2010, seniors who sought YF vaccination at a reference Immunization Center in São Paulo city, Brazil, were included. Demographic and clinical data, previous YF vaccination, travel destination and the final decision regarding YF vaccination or not were collected from standardized medical records. Active AE assessment was done through telephone or electronic mail interview performed approximately 14 d after immunization. CONCLUSION: Most persons aged ≥ 60 y may be safely vaccinated against YF. Before vaccination, they must be carefully screened for conditions associated to altered immunocompetence and for risk of exposure to YF.
Entities:
Keywords:
adverse events following immunization; seniors; yellow fever vaccine
Authors: S Michael Marcy; Katrin S Kohl; Ron Dagan; David Nalin; Michael Blum; Marcy Connell Jones; John Hansen; Jerry Labadie; Lucia Lee; Bryan L Martin; Katherine O'Brien; Edward Rothstein; Patricia Vermeer Journal: Vaccine Date: 2004-01-26 Impact factor: 3.641
Authors: Jane F Gidudu; Gary A Walco; Anna Taddio; William T Zempsky; Scott A Halperin; Angela Calugar; Neville A Gibbs; Renald Hennig; Milivoj Jovancevic; Eva Netterlid; Terri O'Connor; James M Oleske; Frederick Varricchio; Theodore F Tsai; Harry Seifert; Anne E Schuind Journal: Vaccine Date: 2012-04-18 Impact factor: 3.641
Authors: Thomas P Monath; Martin S Cetron; Karen McCarthy; Richard Nichols; W Tad Archambault; Leisa Weld; Philip Bedford Journal: Hum Vaccin Date: 2005-09-02
Authors: James F Jones; Katrin S Kohl; Nooshin Ahmadipour; Gijs Bleijenberg; Dedra Buchwald; Birgitta Evengard; Leonard A Jason; Nancy G Klimas; Andrew Lloyd; Kimberly McCleary; James M Oleske; Peter D White Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: Jane Gidudu; Katrin S Kohl; Scott Halperin; Sandra Jo Hammer; Paul T Heath; Renald Hennig; Bernard Hoet; Edward Rothstein; Anne Schuind; Frederick Varricchio; Wikke Walop Journal: Vaccine Date: 2008-10-23 Impact factor: 3.641
Authors: Nicole P Lindsey; Betsy A Schroeder; Elaine R Miller; M Miles Braun; Alison F Hinckley; Nina Marano; Barbara A Slade; Elizabeth D Barnett; Gary W Brunette; Katherine Horan; J Erin Staples; Phyllis E Kozarsky; Edward B Hayes Journal: Vaccine Date: 2008-09-20 Impact factor: 3.641
Authors: Luiz Antonio Bastos Camacho; Savitri Gomes de Aguiar; Marcos da Silva Freire; Maria da Luz Fernandes Leal; Jussara Pereira do Nascimento; Takumi Iguchi; José Azevedo Lozana; Roberto Henrique Guedes Farias Journal: Rev Saude Publica Date: 2005-06-30 Impact factor: 2.106
Authors: P F Vasconcelos; E J Luna; R Galler; L J Silva; T L Coimbra; V L Barros; T P Monath; S G Rodigues; C Laval; Z G Costa; M F Vilela; C L Santos; P M Papaiordanou; V A Alves; L D Andrade; H K Sato; E S Rosa; G B Froguas; E Lacava; L M Almeida; A C Cruz; I M Rocco; R T Santos; O F Oliva; C M Papaiordanou Journal: Lancet Date: 2001-07-14 Impact factor: 79.321
Authors: Ariane de Jesus Lopes de Abreu; João Roberto Cavalcante; Letícia Wigg de Araújo Lagos; Rosângela Caetano; José Ueleres Braga Journal: Vaccines (Basel) Date: 2022-04-30
Authors: Milton Maciel; Fábia da Silva Pereira Cruz; Marli Tenório Cordeiro; Márcia Archer da Motta; Klécia Marília Soares de Melo Cassemiro; Rita de Cássia Carvalho Maia; Regina Célia Bressan Queiroz de Figueiredo; Ricardo Galler; Marcos da Silva Freire; Joseph Thomas August; Ernesto T A Marques; Rafael Dhalia Journal: PLoS Negl Trop Dis Date: 2015-04-13
Authors: Patrick Cashman; Kristine Macartney; Gulam Khandaker; Catherine King; Michael Gold; David N Durrheim Journal: Int Health Date: 2017-05-01 Impact factor: 2.473